Evidence map›Paper›PMID 36837562›Full record

ArticleMedicina (Kaunas, Lithuania)2023

HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy.

Zuzana Zděblová Čermáková, Pavel Hurník, David Konvalinka, Jan Štembírek, Tereza Paračková, Kamila Resová, Jakub Cvek, Tomáš Blažek, Lukáš Knybel, Martin Formánek and 6 more

Open access · goldAbstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Zuzana Zděblová ČermákováDepartment of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic.ORCID 0000-0002-8668-3732
Pavel HurníkFaculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic.
David KonvalinkaEUC Laboratory CGB, Inc., 703 00 Ostrava, Czech Republic.
Jan ŠtembírekFaculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic.
Tereza ParačkováDepartment of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic.
Kamila ResováDepartment of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic.ORCID 0000-0002-0656-9084
Jakub CvekDepartment of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic.
Tomáš BlažekDepartment of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic.
Lukáš KnybelDepartment of Oncology, University Hospital Ostrava, 708 52 Ostrava-Poruba, Czech Republic.ORCID 0000-0002-2461-6606
Martin FormánekFaculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic.ORCID 0000-0002-5759-2073
Mariam GachechiladzeFaculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic.
Markus JoergerDepartment of Medical Hematology and Oncology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland.
Alex SoltermannFacharzt Foederatio Medicorum Helveticorum (FMH) Pathologie, Pathologie Längasse, 3063 Ittingen, Switzerland.
Jozef ŠkardaFaculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic.
Oldřich MotykaFaculty of Mining and Geology, VŠB-Technical University of Ostrava, 708 33 Ostrava-Poruba, Czech Republic.ORCID 0000-0002-9644-0611
Jana JanoutováFaculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic.
University of Ostrava · CZUniversity Hospital Ostrava · CZPalacký University Olomouc · CZCGB Laboratory · CZCharles University · CZFoederatio Medicorum Helveticorum · CHUniversity of St.Gallen · CHVSB - Technical University of Ostrava · CZ

Funding

Ministry of Health Czech Republic NV19-08-00383RVO-FNOs/2021 27
6 · The paper itself

Abstract

introductionThe incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway.

objectiveThis study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival.

methodTumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined.

resultsOnly two types of HPV were identified-HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (

conclusionWe found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.

Indexed as

Carcinoma, Squamous CellOropharyngeal NeoplasmsPapillomavirus InfectionsHuman papillomavirus 6HumansPrognosisRad51 RecombinaseRAD51 protein, humanRad51 RecombinaseHPVoral cavity canceroropharyngeal cancerRAD51radiotherapy

Identifiers

PMID36837562
PMCPMC9958932
OpenAlexW4320920155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.